{
    "clinical_study": {
        "@rank": "90854", 
        "arm_group": [
            {
                "arm_group_label": "ARM A: BMS-791325", 
                "arm_group_type": "Experimental", 
                "description": "BMS-791325 600 mg tablet orally on 1st and 2nd day, then 900 mg on the 3rd day once a day for 3 days"
            }, 
            {
                "arm_group_label": "ARM B: Moxifloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "Moxifloxacin 400mg tablet orally once on third day"
            }, 
            {
                "arm_group_label": "ARM C: Placebo matching BMS-791325", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo matching BMS-791325 0 mg tablet orally once daily for 3 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether BMS-791325 has an effect on the\n      electrocardiogram (ECG) interval QT corrected for Fridericia's method (QTcF)."
        }, 
        "brief_title": "Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "Primary Purpose: Other: This Phase 1 study is a clinical pharmacology thorough QT study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Healthy men and women, ages 18 to 49 yr old\n\n          -  BMI 18 to 32\n\n          -  Women must not be pregnant or breastfeeding\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  A personal history of clinically relevant cardiac disease, symptomatic or\n             asymptomatic arrhythmias, presyncope or syncopal episodes, or additional risk factors\n             for torsades de pointes (eg, heart failure)\n\n          -  History of hypokalemia, personal history or family history of prolonged QT interval,\n             or family history of sudden cardiac death at a young age\n\n          -  History of biliary disorders, including Gilbert's disease or Dubin-Johnson disease\n\n          -  Inability to swallow multiple tablets consecutively\n\n          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug\n             administration: PR \u2265 210 msec, QRS \u2265 120 msec, QT \u2265 500 msec, QTcF \u2265 450 msec, Heart\n             Rate (HR) < 45 bpm\n\n          -  Second or third degree heart block prior to study drug\n\n          -  Positive urine screen for drugs of abuse\n\n          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human\n             Immunodeficiency Virus (HIV)-1, -2 antibody\n\n          -  Any of the following lab results outside of the ranges specified below prior to\n             dosing:  Alanine aminotransferase (ALT) > upper limit of normal (ULN), Aspartate\n             aminotransferase (AST) > ULN, Total bilirubin > ULN, Direct bilirubin > ULN,\n             Creatinine > ULN,  Serum potassium < lower limit of normal (LLN), Serum magnesium <\n             LLN\n\n          -  History of allergy to Moxifloxacin, BMS-791325, nonstructural protein 5B (NS5B)\n             non-nucleoside inhibitors or related compounds"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02084953", 
            "org_study_id": "AI443-112"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARM A: BMS-791325", 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ARM B: Moxifloxacin", 
                "intervention_name": "Moxifloxacin", 
                "intervention_type": "Drug", 
                "other_name": "Avelox\u00ae"
            }, 
            {
                "arm_group_label": "ARM C: Placebo matching BMS-791325", 
                "intervention_name": "Placebo matching BMS-791325", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Moxifloxacin", 
                "Norgestimate, ethinyl estradiol drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Thomas L Hunt, Site 0001"
            }, 
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }, 
                "name": "Ppd Development, Llc"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-Blinded, Positive-Controlled, Placebo-Controlled, 3-Way Crossover Study to Determine the Electrocardiographic Effects of BMS-791325 in Healthy Subjects", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Difference from placebo of BMS-791325 in time-matched change from baseline (Day -1 on the study) to Day 3 of each period (\u0394\u0394QTcF) at postdose extraction times for the QTcF", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02084953"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference from placebo in time-matched change from baseline (Day -1) to Day 3 at postdose extraction times in the ECG-derived RR or HR and other ECG intervals (PR, QRS, QT). QT is the unadjusted QT interval", 
                "measure": "\u0394\u0394HR, \u0394\u0394PR, \u0394\u0394QRS, \u0394\u0394QT", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 28 days"
            }, 
            {
                "measure": "Number and percent of subjects having a within-period maximum HR, PR, QRS, QT, QTcF, \u0394QT and \u0394QTcF within prespecified categories", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 28 days"
            }, 
            {
                "measure": "Relationship between plasma concentrations of BMS-791325, BMS-794712, and BMS-948158, and the corresponding \u0394\u0394QTcF", 
                "safety_issue": "No", 
                "time_frame": "Approximately 28 days"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "measure": "Time of maximum observed concentration (Tmax) of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "measure": "Area under the concentration-time curve in one dosing interval (AUC(TAU)) of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "measure": "Apparent total oral clearance (CLT/F) of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "measure": "Terminal phase plasma half life (T-HALF) of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "measure": "AUC(TAU) metabolic ratios of BMS-791325, BMS-794712, and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "43 timepoints up to day 26"
            }, 
            {
                "description": "Adverse event (AEs)\nSerious adverse event (SAEs)", 
                "measure": "Incidence of AEs, SAEs, AEs leading to discontinuation and death, marked laboratory abnormalities, findings on 12-lead safety ECG measurements and physical examination, and abnormalities in vital sign measurements exceeding pre-defined thresholds", 
                "safety_issue": "Yes", 
                "time_frame": "Up to  day 28"
            }, 
            {
                "measure": "Difference from placebo of Moxifloxacin in change from baseline (Day -1) to Day 3 at postdose extraction times for the QTcF (\u0394\u0394QTcF)", 
                "safety_issue": "No", 
                "time_frame": "Approximately 28 days"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}